|
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News Archive - March 2022
DLSPH Researcher to Helm $2.5 Million Training and Mentorship Hub in 2SLGBTQ+ Health
March 31, 2022 - By Elaine Smith - An interdisciplinary research team has received a $2.5 million grant from the Canadian Institute of Health Research (CIHR) to develop the 2SLGBTQ+ Health Hub: an intersectional training and mentorship platform. This innovative hub will tackle a major training and capacity gap in intersectional and community-informed 2SLGBTQ+ health and community interventions, drawing on the expertise of a network of over 50 scholars, health professionals, and community leaders from across Canada.
The hunt for an AIDS vaccine approaches 40 with hope and caution
March 31, 2022 - Patrick Boyle - Scientists created a COVID-19 vaccine in under a year, but there remains no vaccine to stop the AIDS virus. Experts explain how HIV eludes defeat and describe their latest strategies.
When researchers discovered the virus that causes AIDS in 1984, then-Health and Human Services (HHS) Secretary Margaret Heckler told a news conference, “We hope to have a vaccine ready for testing in about two years. … Another terrible disease is about to yield to patience, persistence, and outright genius.”
Nearly 40 years later, the world still waits for an AIDS vaccine.
ASICON
13th national conference of AIDS Society of India
31 Mar 2022 - Confronting Pandemics with Proficiency, Precision and Persistence
April 2022 3-5, ITC Kakatiya, Hyderabad
The 13th National Conference of AIDS Society of India - ASICON will be held at a wonderful venue ITC Kakatiya in Hyderabad from 3-5 April 2022 in a Hybrid mode. Whereas we expect 200-250 delegates, subject to local guidelines, in physical mode and rest will be virtual. Besides HIV, Hepatitis B &C, Tuberculosis, this time the scientific agenda of the conference will encompass Covid-19 and other emerging infectious diseases as well.
Read more...
UC San Diego Biology Lab Receives $1.4M Grant to Fight Malaria Spread
March 30, 2022 - By Emerson Dameron - Funding will be used to develop new technologies to boost safety of CRISPR-based genetic strategies
Scientists at the University of California San Diego are hard at work on new genetic technologies intended for use in curbing mosquito populations, fighting the spread of malaria and mitigating the hazards associated with the deployment of gene-editing systems in the wild. That work is now being bolstered by a $1.4 million grant from the Bill & Melinda Gates Foundation.
Estimated number of people (all ages) living with HIV (1990-2020)
Mar 30, 2022 - SciDevNet - A Visualisation of WHO data about Estimated number of people (all ages) living with HIV (1990-2020). Adapted from WHO Global Health Observatory data repository. Read our spotlight article: Cautious optimism for trials of mRNA-based HIV vaccine.
What’s the use of anti-HIV injections when those who need it most can’t use it?
30 Mar 2022 - Who needs a pill or an injection that can prevent them from contracting HIV through sex the most?
Those countries and parts of society with the most new HIV infections, because new infections among HIV-negative people are what such biomedical interventions (treatments and devices that make it harder for the virus to be transmitted) try to stop.
Read more...
Ukrainian Activist Discusses Russian Invasion’s Devastating Impact on HIV Care and Harm Reduction in His Country
March 30, 2022 - Tim Murphy - Like countless people worldwide, we here at TheBody have been horrified, infuriated, and heartbroken at the misery that Russia’s reckless invasion has inflicted on the people of Ukraine. And of course, we’ve also been worried about the roughly 250,000 people—about 1% of the population—living with HIV in Ukraine. In the Eastern Europe and Central Asia region, it’s the second-highest number after Russia. Add to that the fact that Ukraine also has high numbers of people living with tuberculosis—some of it multidrug-resistant—and with active or former injection drug use.
Read more...
Fatty liver disease raises the risk of cardiovascular disease in people with HIV
30 March 2022 - Keith Alcorn - Non-alcoholic fatty liver disease or liver fibrosis raised the risk of cardiovascular disease in people with HIV who have either normal body weight or are under 60, Italian and Canadian researchers report in the journal HIV Medicine.
The study investigators say that people with HIV should ideally be screened for non-alcoholic fatty liver disease (NAFLD) or referred for screening if they have a raised risk of liver fibrosis on laboratory tests, in order to identify people who may be at higher risk of cardiovascular disease.
Read more...
ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV
London, 30 March 2022 - The FDA approval of the first dispersible single tablet regimen containing dolutegravir increases age-appropriate treatment options for children living with HIV
ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi B.V. (Shionogi) as shareholders, has announced that the U.S. Food and Drug Administration (FDA) has approved a new drug application (NDA) for a dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir and lamivudine for the treatment of pediatric patients weighing 10kgs to <25 kgs with human immunodeficiency virus type 1 (HIV-1). In addition, a supplemental new drug application (sNDA) has been approved for Triumeq tablet, lowering the minimum weight that a child with human immunodeficiency virus type 1 (HIV-1) can be prescribed this medicine to 25kgs from 40kgs.
With the flip of a switch, UV-LED lights could be used to kill coronaviruses and other germs: U of T study
March 29, 2022 - By Alexa Battler - Lighting used in offices and public spaces could potentially be used to destroy coronaviruses and HIV.
In a study published this week in Virology Journal, researchers at the University of Toronto killed both viruses using UV-LED lights, which can alternate between white light and decontaminating ultraviolet (UV) light.
Elton John AIDS Foundation Academy Awards Viewing Party Raises $8.6 Million
March 29, 2022 - The 30th annual Elton John AIDS Foundation Academy Awards Viewing Party took place Sunday, March 27, at West Hollywood Park, LA, hosted by 12-time GRAMMY Award-winning singer/songwriter/actress Lady Gaga, Emmy, Tony, and GRAMMY Award-winning artist Billy Porter and Emmy Award-winning actor Eric McCormack, alongside CEO of Rocket Entertainment and chairman of the Elton John AIDS Foundation David Furnish.
The star-studded gala featured a sparkling performance by six-time GRAMMY Award-winning artist Brandi Carlile and raised $8.6 million for the Foundation’s lifesaving work to end AIDS.
Read more...
Largest display of the AIDS memorial quilt.
Mar 29, 2022 - KRON 4
What to know about HIV neuropathy
March 29, 2022 - by Maté Jarai - HIV neuropathy occurs when the virus damages the nerves of the body. When these nerves do not function properly, they are unable to send sensory signals or messages to the central nervous system, brain, or spinal cord. This can cause pain, tingling, and weakness.
Neuropathy is another word for nerve damage. When the nerves experience damage or function incorrectly, numbness, tingling, weakness, or pain can develop.
Read more...
ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for virologically suppressed adolescents living with HIV who are 12 years of age or older and weigh at least 35 kg
Research Triangle Park, NC, March 29, 2022 - The expanded indication for the first and only complete long-acting HIV regimen provides an option with as few as six dosing days per year for virologically suppressed young people living with HIV
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi B.V. as shareholders, today announced that the US Food and Drug Administration (FDA) has approved Cabenuva (cabotegravir, rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents (HIV-1 RNA less than 50 copies per milliliter [c/mL]) who are 12 years of age or older and weigh at least 35kg on a stable antiretroviral regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine.1, 2 The regimen was co-developed as part of a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson. This approval marks the first time a long-acting HIV treatment is available for the adolescent population, underscoring ViiV Healthcare’s commitment to delivering options for young people living with HIV.
Salmonella and Campylobacter continue to show high levels of antibiotic resistance
29 Mar 2022 - Antibiotic resistance in Salmonella and Campylobacter bacteria is still high, says a report released today by the European Centre for Disease Prevention and Control (ECDC) and the European Food Safety Authority (EFSA).
Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere
March 28, 2022 - FOSTER CITY, Calif.-- (BUSINESS WIRE )-- – Funding Will Reach Under-Resourced Communities Most Impacted by the HIV Epidemic and COVID-19 Pandemic –
Gilead Sciences, Inc., (Nasdaq: GILD) today announced $24 million in grants to help reduce health disparities, improve access to quality healthcare, advance medical education and support local communities most impacted by the HIV epidemic and COVID-19 pandemic. The Zeroing In: Ending the HIV Epidemic program, will support 116 organizations in 41 countries. The funding recipients will focus on advancing at least one of three focus areas: Comprehensive HIV Innovation, Digital Health Innovation and Community Outreach and Education.
Deep sequencing of the HIV-1 polymerase gene for characterisation of cytotoxic T-lymphocyte epitopes during early and chronic disease stages
28 March 2022 - Despite multiple attempts, there is still no effective HIV-1 vaccine available. The HIV-1 polymerase (pol) gene is highly conserved and encodes cytotoxic T-lymphocyte (CTL) epitopes. The aim of the study was to characterise HIV-1 Pol CTL epitopes in mostly sample pairs obtained during early and chronic stages of infection.
Read more...
Massive AIDS quilt display set for June in SF
Mar 28, 2022 - by Cynthia Laird - A massive display of the AIDS Memorial Quilt will take place in San Francisco's Golden Gate Park during Pride Month, officials of the National AIDS Memorial Grove, which oversees the tapestry, told the Bay Area Reporter.
Read more...
17 months average wait to switch from a failing HIV treatment regimen in African countries
28 March, 2022 - Roger Pebody - There’s no evidence of an improvement in the capacity of HIV treatment programmes in sub-Saharan Africa to promptly identify treatment failure and to switch patients to second-line antiretroviral therapy (ART), according to a review of 36 observational studies. On average, CD4 counts have already fallen below 200 when treatment failure is recognised and patients wait a further 17 months before changing treatment. Outcomes did not improve between 2009 to 2020, Kerlly Bernabé and colleagues report in the journal Open Forum Infectious Diseases.
Read more...
HIV drugs may lower COVID risk; COVID and flu co-infection raises risk of severe illness, death
March 28 (Reuters) - By Nancy Lapid - Refills every 15 days instead of 3 months
The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.
HIV drugs may curb COVID-19 risk
Read more...
Patients in Tamil Nadu worry as stocks of HIV/AIDS drugs dwindle
MARCH 26, 2022 - European Society of Clinical Microbiology and Infectious Diseases - Refills every 15 days instead of 3 months
A number of antiretroviral drugs are in short supply in parts of Tamil Nadu. Running on low stock, some antiretroviral therapy (ART) centres are disbursing drugs for a duration of 15 days instead of one to three months for many persons with HIV/AIDS, who are under treatment.
Read more...
Early study suggests long-term antiretroviral therapy with protease inhibitors might prevent COVID-19 infection
March 25, 2022 - LISBON, Portugal--(BUSINESS WIRE)-- French study in over 500 people living with HIV suggests that treatment with protease inhibitors was associated with 70% lower risk of COVID-19 infection
A preliminary study to be presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal (23-26 April), suggests that people living with HIV who are on antiretroviral treatment (ART) with protease inhibitors (PI), may have a lower risk of COVID-19 infection. The study is by Dr Steve Nguala from the Intercommunal Hospital Center of Villeneuve-Saint-Georges and the General Hospital of Melun in France and colleagues.
UNITE and AHF to Collaborate on Infectious Disease Elimination and Pandemic Preparedness
March 25, 2022 - LISBON, Portugal--(BUSINESS WIRE)-- UNITE Global Parliamentarians Network to End Infectious Diseases and AIDS Healthcare Foundation (AHF) signed a Memorandum of Understanding this week, outlining their joint work in 2022. With an international pandemic treaty among nations still no closer to completion, it is now more vital than ever that civil society advocacy organizations and governments alike work to fight infectious diseases and prepare to prevent and respond to future pandemics.
New study reveals why HIV remains in human tissue even after antiretroviral therapy
March 25, 2022 - By Tarwinder Rai - Discovery could open the door to new treatments that improve our immune system’s ability to eliminate the stubborn virus.
Thanks to antiretroviral therapy, HIV infection is no longer the life sentence it once was. But despite the effectiveness of drugs to manage and treat the virus, it can never be fully elimi nated from the human body, lingering in some cells deep in different human tissues where it goes unnoticed by the immune system.
Now, new research by University of Alberta immunologist Shokrollah Elahi reveals a possible answer to the mystery of why infected people can’t get rid of HIV altogether.
Ending HIV transmission by Optimizing Pre-exposure prophylaxis in East Asia (HOPE) launch
March 25, 2022 - Associate Professor Jason Ong was recently awarded $667,191 by the National Health and Medical Research Council for an NHMRC e-ASIA 2021 Joint Research Program, “Ending HIV transmission by Optimizing Pre-exposure prophylaxis in East Asia (HOPE)”.
The research program was launched this week. A/Prof Ong, a senior research fellow in the Melbourne Sexual Health Centre, said that HIV is a very significant health issue in the Asia-Pacific region.
PEPFAR and UN Women Announce a Partnership to Strengthen the Leadership and Voice of Young Women in the Global HIV Response
March 25, 2022 - To mark the conclusion of the 66th session of the Commission on the Status of Women, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and UN Women announced a partnership for ‘Investing in Adolescent Girls and Young Women’s Leadership and Voice in the HIV Response’. The United States government is investing over $670,000 for the 12-month partnership, which focuses on elevating the voices of adolescent girls and young women in Sub-Saharan Africa to demand non-discriminatory access to HIV services.
Lessons Learned from Programmatic Gains in HIV Service Delivery During the COVID-19 Pandemic — 41 PEPFAR-Supported Countries, 2020
March 25, 2022 - In 41 U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)–supported countries, overall gains were observed in HIV treatment (5%) and viral load suppression (2%) during the first year of the COVID-19 pandemic. Among countries with the largest overall programmatic gains, strategies that facilitated HIV program improvements included enhanced index testing and community- and home-based testing; multimonth dispensing of medications; streamlining clinic visits; aligning medication pick-up with viral load testing; and improvements in data use.
Read more...
No breakthrough HIV infections seen in women using injectable PrEP
25 March, 2022 - Gus Cairns - A detailed analysis of HIV infections seen in HPTN 084, the study comparing the effectiveness of injectable versus oral HIV pre-exposure prophylaxis (PrEP) in cisgender women, has been published in the Journal of Infectious Diseases. Headline findings were reported in November 2020 when the study was stopped early due to the clearly superior effectiveness of the injections.
Read more...
HIV And AIDs Gets A Sympathetic Update In The New Film "Three Months"
25 March, 2022 - by Mark Young - The coming-of-age film is changing the way we see HIV/AIDS depicted onscreen.
For LGBTQ+ films and television, one of the most common clichés is the AIDS trope, which is basically just an excuse for white, cis-gender, straight-run media organizations to display queer suffering while trying to parade it as acceptance and equality.
This trope is one that follows the queer community to this day, unless you look at Three Months, a new film from director Jared Frieder that offers a fresher and more modern look at what it means to be a queer person dealing with HIV/AIDS.
Read more...
U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment
TITUSVILLE, N.J., March 24, 2022 - Adults living with HIV now have an option to start injectable regimen without the need for an oral lead-in period first
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved a label update for CABENUVA (cabotegravir and rilpivirine), giving healthcare professionals and people living with human immunodeficiency virus (HIV-1) in the U.S. the option to start this once-monthly or every-two-month injectable treatment without the need for the oral lead-in phase (daily cabotegravir and rilpivirine tablets, taken for one month prior to initiation of cabotegravir and rilpivirine injections).1 Clinical data demonstrated the regimen displays a similar safety and efficacy profile both with and without an oral lead-in period.2CABENUVA was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s decades-long commitment to combatting HIV.
Could CAR T cells offer hope for an HIV cure?
SSACRAMENTO - March 24, 2022 - UC Davis Health researchers aim to use CAR T cells to target HIV cells to control the virus without medication
UC Davis Health researchers have launched a novel study looking to identify a potential cure for HIV. Using immunotherapy, researchers will take a patient's own white blood cells, called T-cells, and modify them so that they can identify and target HIV cells to control the virus without medication.
Worldwide, almost 38 million people are living with HIV, the virus that can lead to AIDS. Roughly 75% of them receive antiviral treatment, according to UNAIDS. In California, 150,000 people live with HIV and 68% of these individuals are virally suppressed due to treatment.
Sir Elton John says he’s ‘unbelievably lucky’ as he celebrates 75th birthday
March 24, 2022 - By Kerri-Ann Roper and Ellie Iorizzo - The veteran hit-maker acknowledged his milestone birthday.
Sir Elton John has said he is determined to keep “giving back to the industry that has given me so much” as he turns 75.
Read more...
AHF Says, “Invest in Health: Get Tested for HIV & TB” on World TB Day!
March 24, 2022 -- LOS ANGELES--(BUSINESS WIRE)-- Even though tuberculosis (TB) is entirely preventable and treatable, more than 4,100 people lose their lives every day to TB, and nearly 28,000 more acquire the virus. On this World TB Day, AIDS Healthcare Foundation (AHF), in addition to urging governments worldwide to increase resources to fight the deadly disease, encourages people everywhere to "Invest in Health: Get tested for HIV & TB!"
PAST AS PROLOGUE: COVID-19, HIV AND OTHER INFECTIOUS DISEASE INEQUITIES BY RACE/ETHNICITY
March 24, 2022 - April 4 @ 1:00 pm - 2:00 pm (Zoom)
Speaker: Gregorio Millett, MPH, vice president and director of public policy at amfAR
Examining and addressing inequities by geography, income, race/ethnicity, sex or other characteristics is a cornerstone of public health science and practice. The most recent and salient example of health inequities is the COVID-19 pandemic. As with HIV, H1N1 and other preceding pandemics, COVID-19 followed a predictable (though accelerated) path in the United States: Black, Latinx and Native populations were overly represented in U.S. cases, hospitalizations and deaths within months of the first confirmed case of SARS-CoV-2.
Tuberculosis remains one of the deadliest infectious diseases worldwide, warns new report
24 Mar 2022 - According to the latest European Centre for Disease Prevention and Control (ECDC)/World Health Organization (WHO) report on tuberculosis (TB) surveillance and monitoring in Europe, a sharp drop (24%) in reported tuberculosis cases between 2019 and 2020 was probably exacerbated by the COVID-19 pandemic, which hindered detection and reporting. Tuberculosis remains one of the world’s deadliest infectious diseases, second only to COVID-19, and drug resistant TB strains are still a major concern. In the fight against tuberculosis, urgent investment is critical, especially in the context of the ongoing pandemic.
ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period
London, 24 March 2022 - US FDA approval of updated label streamlines the initiation process for the first and only complete long-acting HIV treatment by allowing people to start directly with injections
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved a label update for Cabenuva (cabotegravir, rilpivirine) making the oral lead-in with cabotegravir and rilpivirine tablets optional. Oral cabotegravir and rilpivirine can be taken for a month to assess tolerability to the medicines prior to initiating cabotegravir and rilpivirine injections, a regimen co-developed as part of a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, but this oral lead-in is now optional after clinical trial data demonstrated similar safety and efficacy profiles for both initiation methods (with or without the oral lead-in).1, 2
Canada Is the First to Approve Long-Acting HIV Regimen Cabenuva
March 23, 2022 - By Benjamin Ryan - The FDA recently held up the U.S. approval based on concerns over the monthly injectable regimen’s manufacturing.
HIV treatment has entered an exciting new era as Canada has become the first nation in the world to approve ViiV Healthcare’s monthly long-acting injectable antiretroviral (ARV) regimen Cabenuva (cabotegravir/rilpivirine)—the first complete regimen for treating the virus that does not require daily pills.
Read more...
‘The infectious disease that nobody ever thinks about’
March 23, 2022 - Before COVID, tuberculosis was the leading infectious disease killer in the world. To mark World TB Day, March 24, Sarah Fortune, John LaPorte Given Professor of Immunology and Infectious Diseases and a TB expert, discusses the state of the disease worldwide, obstacles to fighting it, and the latest research.
Read more...
Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy
March 23, 2022 - HIV-infection is known to aggravate the course of many infectious diseases, including COVID-19. International guidance recommends vaccination of HIV+ individuals against SARS-CoV-2. There is a paucity of data on epidemiological efficacy assessment of COVID-19 vaccines among HIV+. This paper provides a preliminary assessment of Sputnik V vaccine effectiveness in HIV+ patients on antiretroviral therapy (ART).
Read more...
Why are HIV infections more virulent in heterosexual people?
March 23, 2022 - Written by Eleanor Bird, M.S. - A recent study included more than 340,000 people across the world with an HIV-1 infection.
The way that a virus is transmitted influences the severity of the disease it causes, or virulence.
Read more...
Can CAR-T Therapy Enhanced With Autophagy Drugs Lead to an HIV Cure?
March 23, 2022 - By Trent Straube - An amfAR grant will help find out. Plus, the AIDS research group also awards three new Mathilde Krim HIV fellowships.
Over half a million dollars was awarded to HIV scientists in the latest round of grants from amfAR, The Foundation for AIDS Research. Specifically, Anjie Zhen, PhD, of the University of California at Los Angeles received a $100,000 research grant to explore a unique method of boosting CAR-T therapy in hopes of leading to an HIV cure. And three young grantees each received a Mathilde Krim fellowship of $150,000. The fellowships are named after Krim, who helped found amfAR and publicly fought prejudice against those living with HIV.
Read more...
Impact of COVID-19 hits hard as TB deaths among people living with HIV rise for the first time since 2006
GENEVA, 23 March 2022 - On World Tuberculosis Day 2022, UNAIDS is calling for urgency in diagnosing and treating TB as TB deaths among people living with HIV rise for the first time after years of progressive decline
Tuberculosis (TB) is the leading cause of death among people living with HIV, accounting for around one third of AIDS-related deaths globally. Coordinated and scaled up efforts to prevent, diagnose and treat the two diseases had resulted in a 68% decline in TB deaths among people living with HIV between 2006 and 2019. However, in its 2021 Global Tuberculosis Report, the World Health Organization announced that TB deaths among people living with HIV increased for the first time in 13 years, from 209 000 in 2019 to 214 000 in 2020.
Ukraine war shutters HIV clinics, disrupts drug supplies
Mar 22, 2022 - Benjamin Ryan, Thomson Reuters Foundation - In basement shelters and makeshift clinics, Ukrainian doctors are striving to keep treatment for HIV-positive people on track as Russia’s invasion raises fears that years of progress to combat the virus could be undone.
Read more...
Standing on the sidelines was no longer an option
March 22, 2022 - By Hank Trout, MA - Paying tribute to the selfless volunteers in the early fight against AIDS.
As San Francisco AIDS Foundation commemorates its fortieth year of service, we caught up with four of those ordinary people who did, and continue to do, much-needed, substantive work in the HIV/AIDS community. Ed Wolf, Cal Callahan, Harry Breaux, and Joanie Juster are all well known and loved in this community for their innumerable hours of volunteer work, their compassion, and their undying dedication to the fight against AIDS.
Read more...
HIV Diagnosis Market to Grow at a CAGR of 12.35% during 2022-2028; Increasing Prevalence of HIV Infection & Government Initiative to Eradicate HIV/AIDS will Drive Growth: The Brainy Insights
Pune, March 21, 2022 (GLOBE NEWSWIRE) -- Increasing healthcare spending and rising awareness about HIV/ AIDS are driving the growth of the HIV diagnosis market in the North America region.
As per the report published by The Brainy Insights, the global HIV diagnosis market is expected to grow from USD 2.59 billion in 2020 to USD 6.45 billion by 2028, at a CAGR of 12.35% during the forecast period 2021-2028.
HIV prevalence is increasing rapidly in almost every geographic region and becoming one of the major public health crisis in the world. As per the U.S. Department of Health & Human Service data, there were about 37.9 million people across the globe with HIV/AIDS. Approximately 1.7 million individuals in the world are newly infected in the year 2018. Around 79% of total infected people are aware of their HIV infection, and 21% of people are still needed to access the HIV testing service.
Ukrainians displaced by Russian invasion struggling to access HIV and drug dependency treatment
21 March, 2022 - Rosalie Hayes - Considerable efforts are underway to support Ukrainian refugees and internally displaced people to access the HIV and drug dependency treatment they need, the European Union’s HIV/AIDS, Hepatitis and TB Civil Society Forum heard on Wednesday 16 March.
Read more...
Activists stage 'die-in' to call for more HIV/AIDS funding
Mar 21, 2022 - by Eric Burkett - Evoking memories of earlier angry protests, participants at a San Francisco City Hall rally for increased HIV support staged a dramatic "die-in" after speakers demanded political leaders recommit to fighting the disease with increased funding.
Read more...
Brown study shows suspending syringe services programs would lead to increase in HIV infections
March 21, 2022 - By Anna Kim - Study uses simulation model to project HIV incidence from 2020 to 2025
Last month, a study published by University researchers used a simulation model to show that suspending syringe services programs would lead to an increase in HIV infections.
Read more...
UNAIDS Executive Director’s message on International Day for the Elimination of Racial Discrimination
21 March 2022 - Winnie Byanyima - It has been more than half a century since the United Nations proclaimed the 21 March as the International Day for the Elimination of Racial Discrimination. On that day in 1960 police opened fire on a crowd of peaceful protesters standing up and speaking out against apartheid in South Africa. Dozens were killed that day. It took a further 30-year bitter battle for apartheid legislation to be repealed, during which time millions of black Africans were removed from their homes and forced into segregated neighbourhoods. The world said never again…
Yet today racism continues to thrive, deepening inequalities, fracturing societies and denying people their basic human rights, including their right to health.
HIV medication can also be used for young children, new research shows
MARCH 20, 2022 - An existing drug used to treat people with HIV has been proven to be effective and safe for younger children, according to research published by Radboud UMC. The medication, Dolutegravir, can be given to children who weigh less than 20 kilograms, they said. The World Health Organization (WHO) has since incorporated the findings into its guidelines.
Read more...
In wake of COVID, advocates for HIV care seek return to spotlight
March 20, 2022 - Erin Allday - San Francisco’s aggressive, nationally recognized push to drive HIV infections to near zero and improve the health of those living with the virus took a discouraging hit during the COVID pandemic, as attention citywide focused on a new and different public health crisis.
Read more...
Unitaid to introduce new long-lasting injection to prevent HIV in Brazil and South Africa, as high-income countries begin deployment
GENEVA, 18 March 2022 - People at risk of HIV in Brazil and South Africa will be among the first to benefit from a highly effective, long-acting injectable HIV preventive treatment through two large-scale operational projects funded by global health agency Unitaid.
Long-acting cabotegravir is a new HIV prevention method that provides eight weeks of continuous protection against HIV infection through a single intramuscular injection.
DIFFA BY DESIGN TAKES CENTER STAGE IN NYC, MARCH 24-26, 2022
NEW YORK, March 18, 2022 (GLOBE NEWSWIRE) - Three-Day Fundraiser Features Gala with Special Guest Tony Award®-Winning Actor Jane Krakowski and Live Performances from Broadway Stars, a Dance Party, Captivating Programming, Shoppable Experiences, Inspiring Installations, & More…
DIFFA BY DESIGN is next week, Thursday, March 24 to Saturday, March 26, 2022 at Center 415 (415 Fifth Avenue) in NYC. The event promises a fun and immersive experience, all with the goal of raising funds for DIFFA in their efforts to combat AIDS, homelessness, food scarcity, and mental health issues across the country. Top NY design talent will create inspiring and instagrammable installations that are open to consumers and design cognoscenti alike. Ticketed events include a formal Gala with Broadway stars and a late-night cocktail/dance party. Attendees can also attend talks, shoppable experiences and weave a textile made with recycled materials.
HHS Announces Nearly $44 Million to Strengthen Mental Health and Substance Use Services for Populations at Risk for or Living with HIV/AIDS
March 18, 2022 - Today, the Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), announced three funding opportunities to strengthen mental health and substance use services for individuals at risk for or living with HIV/AIDS. Totaling $43.7 million dollars, the funding opportunities reflect the Biden-Harris Administration’s commitment to providing accessible, evidence-based, culturally appropriate substance use prevention, treatment and recovery services to all as part of HHS’s new Overdose Prevention Strategy. Funding will be awarded in the fall.
UNAIDS welcomes parliament’s decision to repeal the law that criminalizes HIV transmission in Zimbabwe
GENEVA, 18 March 2022 - UNAIDS congratulates Zimbabwe’s parliament for repealing section 79 of the Criminal Law Code, which criminalizes HIV transmission. A new marriage bill adopted by parliament that repeals the criminal code section is to be signed into law by the president. The criminalization of HIV transmission is ineffective, discriminatory and undermines efforts to reduce new HIV infections. Such laws actively discourage people from getting tested for HIV and from being referred to the appropriate treatment and prevention services.
Siran Koroukian, PhD, leads CWRU study on Cancer in Men Living with HIV
March 17, 2022 – Researchers led by Case Western Reserve University demonstrate a high prevalence of cancer among men living with HIV
Accompanying editorial: Findings point to the importance of early cancer screenings among men with HIV
Researchers with Case Western Reserve University have found that there are nearly twice as many men with cancer among men living with HIV (MLWH) compared to men who do not have the human immunodeficiency virus. The rates of cancer are even higher in men with symptomatic HIV.
UCLA’s HIV prevention and treatment center receives $7.5 million grant from NIH
March 17, 2022 - Enrique Rivero - The National Institute of Mental Health has renewed its support for UCLA’s collaborative Center for HIV Identification, Prevention and Treatment Services, or CHIPTS, with a five-year, $7.5 million grant.
The center, made up of leading scientists from UCLA, Charles R. Drew University of Medicine and Science, the Friends Research Institute and the RAND Corp., has worked for 25 years to combat the HIV/AIDS epidemic both locally and globally through scientific research and treatments, network building and collaborations with community and agency partners.
Lessons from Flu and HIV Inspire Universal Coronavirus Vaccine
March 17, 2022 - Ricki Lewis, PhD - Masks are coming off and we’re venturing back into the world, thanks largely to vaccines and natural immunity. Still, viral evolution continues. SARS-CoV-2 will continue to spawn mutations that will gather, with older mutations, into ever new variants.
London, Ont., advocate works to get the word out about little-known HIV-prevention pill
Mar 17, 2022 - James Chaarani - He says that more physicians know about the regime because of their initatives
There's a daily pill out there that can prevent the spread of HIV by over 90 percent, but is a lot of people who need it, don't know about it. That's why a London, Ont. advocate has been working to change that.
Read more...
People with HIV more likely to develop high blood pressure after starting an integrase inhibitor
17 March, 2022 - Keith Alcorn - People with HIV taking integrase inhibitors were more likely to develop high blood pressure than those taking non-nucleoside reverse transcriptase inhibitors (NNRTIs), a large international cohort study has reported.
People taking protease inhibitors were also at greater risk of developing high blood pressure, the study found.
Read more...
Study shows Biktarvy for PEP has fewer side effects and better completion rates
16 March, 2022 - José Carlos Mejía Asserias - Patients at a study at Fenway Health taking a daily single pill of the fixed drug combination bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) for PEP after sexual exposure had fewer side effects and better completion rates than participants in previous studies of other PEP regimens, Professor Kenneth Mayer and colleagues report in the Journal of Acquired Immune Deficiency Syndromes.
Read more...
Ukraine’s Ticking Time Bomb: Women, War and HIV
3/16/2022 - by JESSICA HENN - With disturbing parallels to former conflicts, wartime sex work and increases on HIV rates are sure to rise as a result of the Ukraine-Russia conflict.
Ukraine has the second largest HIV epidemic in eastern Europe and central Asia, with an estimated 250,000 people living with HIV. These rates have, in a large part, been spurred by militarization and conflict in the country, factors which have disproportionally affected women, increasing their vulnerability to HIV infection and exposing them to stigma, marginalization and violence.
Read more...
Increased support needed for a coordinated global HIV and COVID-19 response
SEATTLE (Mar. 15, 2022) - Leading infectious disease researchers called for a coordinated response to HIV and COVID-19 globally, building on the successes of key donor programs such as the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program and Global Fund to Fight AIDS, TB and Malaria (GFATM) in a new perspective piece published in The Journal of the American Medical Association.
Study Shows mRNA Vaccine Technology Can Be Used For HIV Vaccines
DURHAM, N.C. - March 15, 2022 - Using mRNA technology like that in the COVID-19 vaccines, researchers have demonstrated a successful way to deliver a potential HIV vaccine, researchers at Duke Human Vaccine Institute report.
Publishing online March 15 in the journal Cell Reports, the research team describes an important advancement in what is a complex vaccine development process. The approach uses mRNAs within lipid nanoparticles that are capable of stimulating HIV antibodies.
War in Ukraine risks reversing gains in fight against HIV, tuberculosis
March 15, 2022 - BY CARLO MARTUSCELLI AND LILY HYDE - Fighting, chaos and refugee flows create the perfect conditions for spreading disease.
Russia’s invasion of Ukraine could spark an upsurge in HIV and tuberculosis and undo a decade of gains in public health, experts warn.
Read more...
What does ‘living with’ COVID-19 mean? HIV/AIDS activists offer lessons from pandemics past
Mach 16, 2022 - ZOSIA BIELSKI - When LGBTQ communities helped researchers turn HIV from a death sentence into a chronic illness, they gained a new perspective on risk, social stigma and the duty of care – insights that are still critical now
As COVID-19 hospitalizations decline and restrictions loosen across the country, boosted Canadians are slowly moving beyond the crisis stage of the pandemic. But a new phase brings new questions: What does it mean for a population to “live with” COVID-19, in the long term? What can be done to temper the social divisions that persist around this virus? How do we deal with its lingering effects, including long COVID? Two years since the pandemic took hold, how do we calibrate risk and function alongside it?
Read more...
Late HIV diagnosis of older people is an increasing problem, in most parts of the world
15 March, 2022 - Roger Pebody - Among people diagnosed with HIV over the age of 50, the proportion diagnosed at a late stage is higher than among younger people, in almost all global regions examined by Professor Amy Justice of Yale University in The Lancet HIV. While rates of late diagnosis have fallen among younger people in many regions in recent years, there has been less progress for older people.
Read more...
Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine
March 14, 2022 - Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574).
New poster exhibit documents urgency, complexity of HIV/AIDS messaging
March 14, 2022 - The first major exhibition of the University’s AIDS Education Posters highlights the role of poster art during the global epidemic.
Thought-provoking. Myth-busting. Visually arresting. Painfully blunt.
However you describe it, the new exhibit presented by the Memorial Art Gallery (MAG) and the River Campus Libraries (RCL) at the University of Rochester captures the creative lengths taken to prevent and mitigate the tragedy and destruction caused by the HIV/AIDS epidemic.
Read more...
NIH launches clinical trial of three mRNA HIV vaccines
March 14, 2022 - Phase 1 study is among first to examine mRNA technology for HIV.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a Phase 1 clinical trial evaluating three experimental HIV vaccines based on a messenger RNA (mRNA) platform—a technology used in several approved COVID-19 vaccines. NIAID is sponsoring the study, called HVTN 302, and the NIAID-funded HIV Vaccine Trials Network (HVTN), based at Fred Hutchinson Cancer Research Center in Seattle, is conducting the trial.
'Culture is the medicine we need': Indigenous-centred HIV program launched in Vancouver
Mar 13, 2022 - David P. Ball - Caring for people with HIV requires culturally sensitive approaches, says advisor to Dr. Peter AIDS Foundation
A health-care facility in Vancouver unveiled a new initiative for Indigenous people living with HIV.
Vancouver's Dr. Peter Centre, which specializes in care for people with HIV/AIDS, announced on Friday that it had received funding to hire dedicated staff and to launch an Indigenous-centred program called "Culture of Care."
Read more...
Princess Stéphanie of Monaco pleads for Ukrainians with HIV/AIDS as access to life saving drugs is impacted by conflict
13th March 2022 - By Maddalena Mastrostefano - Princess Stéphanie of Monaco offered her support to Ukraine and launched a programme to help a special category of refugees during an event marking International Women’s Day.
Her Serene Highness is President of Fight AIDS Monaco, an organisation focussed on the fight against HIV/AIDS, and was taking part in an event on 8 March, during which she made her position clear.
Read more...
'They Call Me Magic': NBA star Earvin Johnson embraces his HIV status as his 'purpose'
AUSTIN, Texas - March 12, 2022 - Erin Jensen - Legendary basketball player Earvin "Magic" Johnson, who earned the moniker “Magic” for his superior talents as a high school baller, debuted the first episode of his Apple TV+ series “They Call Me Magic” Saturday at Austin’s South by Southwest festival. The four-part project, directed by Rick Famuyiwa (“Dope," "The Wood”), streams starting April 22.
Read more...
Finally! A condom approved for anal sex
March 11, 2022 -By Charles Orgbon III - The FDA has finally given guidance on condom use for anal sex. Here's what the research shows--and what it means for you.
“Wear a condom” — it’s the first sex education many of us receive.
Read more...
Director of Center for Aging and HIV: Increasing Patient Lifespan and ‘Healthspan’
MAR 10, 2022 - BY MELISSA ROHMAN - Frank Palella, MD, the Potocsnak Family – C.S.C. Professor of Medicine in the Division of Infectious Diseases, joined Northwestern University Feinberg School of Medicine faculty in 1992 after completing his internal medicine residency and infectious diseases fellowship at Northwestern’s McGaw Medical Center. He began his tenure shortly after the height of HIV/AIDS epidemic and has since become a world-renowned expert in sexually transmitted diseases and leader in optimizing care for patients.
HIV and AIDS is also common in women and girls, not just men
Mar 10, 2022 - Cynthia Puga - KENNEWICK, Wash. - HIV and AIDS are not only common in men, but in women as well.
The Communicable Diseases Program Manager, Heather Hill, says a lot of people think this is a disease that only men can get. "This day is so important because women are at risk and can get HIV," she explained.
Read more...
Understanding modern infectious diseases and their impacts
March 8, 2022 - Newswise - Curbing or even containing a pandemic breakout like COVID-19 almost always implies unpalatable choices between lost lives and livelihoods. The authors of a new study just published in the Journal of Economic Literature set out to better understand the impacts and trade-offs policymakers must consider when addressing modern infectious diseases and their macroeconomic repercussions.
Canadian Inuit HIV AIDS Network (CIHAN)
CIHAN members provide Pauktuutit with updates on their respective regions in the areas of sexual health, hepatitis C and HIV/AIDS. In this way, CIHAN helps to facilitate Pauktuutit’s outreach to Inuit communities and groups and collaborates with the Canadian Aboriginal AIDS Network. CIHAN also functions as a mechanism to share information on HIV/AIDS across all regions.
Read more...
Diagnosed 28 yrs ago, Jane Costello is one of 3,300 women living with HIV in Australia
March 8, 2022 - by Jane Costello - Wednesday 9 March 2022 marks the seventh National Day of Women living with HIV.
28 years ago, I received a life-altering diagnosis. HIV. As a married heterosexual monogamous woman, contracting HIV was inconceivable! What followed was 10 years of questioning and grieving, under an unbearable burden of secrecy. It was also a time of discovering myself and what was important to me.
Read more...
A potential cure for HIV: Right under our belly buttons?
March 8, 2022 - by Niamh Stafford - At the 2022 Conference for Retroviruses and Opportunistic Infections, Yvonne Bryson, an infectious disease researcher and professor at the University of California at Los Angeles, announced that a woman of mixed race had been cured of human immunodeficiency virus (HIV). After undergoing an umbilical cord stem cell transplant to treat her leukemia, the patient exhibited signs of HIV remission. Scientists are hopeful that this research on umbilical cord stem cells could shed light on a potential cure for HIV.
Prevention and control of infectious diseases in the context of Russia’s aggression towards Ukraine
March 8, 2022 – Persons fleeing from Ukraine may be vulnerable to developing certain infectious diseases as a result of their living conditions and the situation they face during displacement.
ECDC published Operational Considerations for the prevention and control of infectious diseases in the context of Russia’s aggression towards Ukraine on 8 March.
Since the escalation of aggression towards Ukraine that started on 24 February 2022, and as of 7 March 2022, over 1.7 million people have fled to Poland, Hungary, Moldova, Romania, and Slovakia, according to the United Nations Refugee Agency (UNHCR).
UNAIDS Executive Director's message on International Women’s Day 2022
8 March 2022 - Winnie Byanyima - Congratulations on International Women’s Day to all whose determination and solidarity is the light of hope and the power for change.
Women are not waiting to be offered a seat at the table, they are bringing their own fold-up chair.
This year’s theme calls for “Gender equality today for a sustainable tomorrow”. As the women’s movements have brought to the fore, and as all the evidence demonstrates, every development goal depends on ensuring the rights of all women and girls.
New HIV mRNA vaccine study gets boost from COVID mRNA vaccine development
March 07, 2022 - by Adam Pope - With as much turmoil and negativity as the COVID-19 pandemic has supplied, there may be a silver lining when it comes to a new vaccine study for those suffering with HIV.
The first study participant has been enrolled in a new Phase 1 clinical trial using the messenger ribonucleic acid, or mRNA, vaccine technology developed by Moderna to evaluate the safety and immune responses of three different experimental vaccines against HIV. This randomized, open-label trial represents one of the first clinical studies of the use of mRNA vaccine technology against HIV.
Long COVID more common in people with HIV
7 March 2022 - Keith Alcorn - Unvaccinated people with HIV were four times more likely than HIV-negative people to experience ‘long COVID’ symptoms after acute COVID-19 illness and these symptoms were associated with higher levels of inflammatory markers, a small study conducted by HIV researchers at University of California San Francisco has found.
Read more...
Weill Scientists Explain Breakthrough in Potential HIV Cure
March 6, 2022 - By Tiffany Adjei-Opong - Four years ago, a team of research physicians at Weill Cornell Medicine began treatment for an HIV patient, in the hopes of finding a cure. This February marked 14 months since the patient was free of the virus, presenting scientists with a novel treatment to combat HIV.
Read more...
ViiV will not license new game-changing long-acting HIV prevention drug to generic manufacturers
04 MARCH 2022 - Pharmaceutical corporation ViiV has just announced they will not pursue a voluntary licensing deal for long-acting injectable cabotegravir (CAB-LA) to allow generic production and affordable prices for low- and middle-income countries (LMICs). The drug is patented in many countries including India, Brazil and South Africa, and these patent barriers have a chilling effect on the development of low-cost generic formulations.
National AIDS Memorial Announces Second Recipient of the Mary Bowman Arts in Activism Award
SAN FRANCISCO, March 3, 2022 /PRNewswire/ -- Now accepting applications for the next awards for the HIV/AIDS and social justice program funded through the support of ViiV Healthcare
The National AIDS Memorial announced today that Sarah Frank, a freshman at Brown University in Providence, Rhode Island is the second recipient of the Mary Bowman Arts in Activism Award. The Award honors the life of Mary Bowman, the young poet, advocate, author, and singer living with AIDS, who passed away in early 2019 at the age of 30.
Funded through a multi-year grant from ViiV Healthcare, the Award offers support to artist-activists who are working and committed to making a difference in the fight against HIV/AIDS and advancing social justice.
Jammeh, Dr. Mbowe to face justice over 41 deaths of HIV/AIDs patients
Mar 3, 2022, - Among the alleged number of atrocities the former President Jammeh must answer to if he is to eventually face justice, is the HIV/AIDs treatment known as the President's Alternative Treatment Programme (PATP), which claimed at least 41 lives of HIV/AIDs patients, according to the TRRC report.
Read more...
A Statement from the Global Virus Network on the 2022 Russian Invasion of Ukraine
BALTIMORE, MD, March 3, 2022: The Global Virus Network (GVN) is an apolitical global organization comprised of the world’s leading scientists, including those from Russia and Ukraine, who specialize in education and research for the purpose of protecting mankind from viral proliferation and viruses that cause pandemics. The scientists of the Global Virus Network collaborate to alleviate the pain and suffering caused by viral pathogens and to mitigate the threat they pose to mankind.
THE FLORIDA DEPARTMENT OF HEALTH IN MIAMI-DADE COUNTY RECOGNIZES NATIONAL WEEK OF PRAYER FOR THE HEALING OF HIV/AIDS
Sing for a Cure Concert with Le’Andria Johnson. In observance of the National Week of Prayer for the Healing of HIV/AIDS. Friday March 11, 2022.
Antioch Baptist Church: 21311 NW 34th Ave, Miami Gardens, FL
The National Week of Prayer for the Healing of AIDS (NWPHA) is an annual HIV awareness campaign that mobilizes faith communities and highlights the contributions and impact congregations are making in areas of HIV prevention, testing, direct service, advocacy, and community engagement. The NWPHA is an initiative of the Balm in Gilead.
Beginning Sunday, March 6th - Saturday, March 12, 2022; worship centers such as churches, synagogues, mosques; as well as other faith-based organizations are requested to pause for a moment of prayer for the healing of HIV/AIDS during their worship service where they will provide AIDS information to their communities.
The Innovate Fund Provides $12.5 Million Financing for Renovation of Most Comprehensive HIV/AIDS Facility in the US
ATLANTA, March 2, 2022 /PRNewswire/ -- Renovation will soon be underway at the Grady Ponce De Leon center, an HIV/AIDS clinic providing various medical and support services for people living with HIV/AIDS, due to investment from The Innovate Fund. The Innovate Fund, a New Markets Tax Credits (NMTC) Community Development Entity, provided $12.5 million to assist in the rehab of the facility's five existing operational floors.
Up Against the Wall
Up Against the Wall: Art, Activism, and the AIDS Poster
March 6 – June 19, 2022
Up Against the Wall: Art, Activism, and the AIDS Poster is the first major exhibition devoted to the University of Rochester’s vast collection of HIV/AIDS-related posters. The exhibition features 165 of the most visually arresting and thought-provoking posters from the over 8000 posters from 130 countries assembled by collector, physician, and medical historian Dr. Edward C. Atwater. Dr. Atwater generously donated the entire collection, which also includes a broad range of AIDS-related ephemera, to the University’s River Campus Libraries’ Department of Rare Books, Special Collections, and Preservation beginning in 2007. Today it comprises one of the largest collections of its kind in the world. Both the collection and the exhibition illustrate the wide range of communication strategies used to educate and inform people about this devastating global epidemic, underscoring how beauty and creativity have grown out of the tragedy and destruction of this deadly virus.
Top 5 HIV cure and vaccine stories from CROI 2022
2 March 2022 - Roger Pebody - HIV researchers present some of the most important and cutting-edge science each year at the Conference on Retroviruses and Opportunistic Infections (CROI). This year’s conference included promising studies on broadly neutralising antibodies and a case report that generated headlines around the world.
Read more...
FDA rejects Gilead’s HIV drug lenacapavir over glass vial concerns
March 02, 2022 - By
Caitlyn Stulpin - The FDA has rejected Gilead Science’s new drug application for a long-acting HIV drug over concerns with the proposed glass vials in which the drug would be stored, according to a press release.
Read more...
Pedro Zamora Scholarships Awarded to 11 Young HIV Leaders
March 2, 2022 - By Trent Straube - MTV Real World star Pedro Zamora would have turned 50 this week. These youth scholarships honor his AIDS education legacy.
Born on February 29, 1972, reality TV star and international AIDS activist Pedro Zamora would have turned 50 this week. But as the world witnessed in November 1994, he died of AIDS-related illness at age 22, one day after MTV aired the final episode of The Real World: San Francisco. The third season of the hit reality series had shot Zamora to stardom earlier that year, giving the gay Cuban American a platform to educate about HIV and stigma and LGBTQ issues.
Read more...
Top 5 HIV cure and vaccine stories from CROI 2022
2 March 2022 - Roger Pebody - HIV researchers present some of the most important and cutting-edge science each year at the Conference on Retroviruses and Opportunistic Infections (CROI). This year’s conference included promising studies on broadly neutralising antibodies and a case report that generated headlines around the world.
Read more...
Top 5 stories on HIV, ageing and co-morbidities from CROI 2022
2 March 2022 - Roger Pebody - An enormous quantity of important and fascinating HIV research is presented each year at the Conference on Retroviruses and Opportunistic Infections (CROI). We have published 30 news articles from this year’s conference. As it is hard for anyone to keep up, here is a round-up of the latest research on COVID-19 and other health issues facing people living with HIV.
Read more...
Study: Increase in Condom Use Has Potential to Significantly Decrease New HIV Infections
ALBANY, N.Y. (March 1, 2022) - An increase in condom use has the potential to prevent one in 11 new HIV infections among adolescent males who have sexual contact with other males, according to hypothetical modeling work out of the School of Public Health.
Intermingling between populations may contribute to HIV spread
March 1, 2022 - Findings suggest community-based HIV prevention efforts may need to consider geographic transmission patterns if they are to effectively curb the spread of the disease.
Sexual partnerships between individuals from different communities may help explain why some community-based HIV prevention efforts were moderately effective, shows a study published today in eLife.
The findings may help explain the results of some community-based prevention studies and help scientists develop better ways to track and prevent the spread of HIV.
The Gambia: HIV patients recount herbal treatment under Jammeh
1 Mar 2022 - By Nicolas Haque - Former president Yahya Jammeh claimed he could cure people suffering from HIV and Aids. Jammeh treated hundreds of patients in Gambian clinics, administering herbal remedies.
Watch Video...
Misinformation
March 1, 2022 - On March 1, 2022 at 1 pm Curator and SNMA Executive Director, Hunter O'Hanian, provided a tour and curatorial talk of the exhibition, Misinformation: True and Not-So True Early Information About AIDS, in the Charles L. Ross Gallery at Stonewall National Museum & Archives.
Gambians pursuit of justice for Jammeh’s bogus AIDS cure
MARCH 1, 2022 - BY SARAMBA KANDEH - International bodies did little when the president forced patients to take his fake remedy. They can start to make amends by supporting Gambians now.
In January 2007, The Gambia’s then-president Yahya Jammeh declared to the world that he could cure HIV/AIDS with a herbal concoction. Soon after, he established a nightmarish “treatment programme” to administer this destructive hoax.
Billy Porter, Lady Gaga & Eric McCormack to Co-host Elton John Aids Foundation Academy Awards Viewing Party
LONDON, March 1 (Reuters) - The viewing party will be on March 27, 2022.
Elton John AIDS Foundation is pleased to announce Academy Award® and 12-time GRAMMY® Award-winning singer/songwriter/actress Lady Gaga, Emmy®, Tony®, and GRAMMY Award-winning artist Billy Porter and Emmy® Award-winning actor Eric McCormack are set to co-host the 30th Annual Elton John AIDS Foundation Academy Awards Viewing Party alongside David Furnish on March 27, 2022.
Read more...
Fears of HIV medicine shortages and disease in Ukraine after Russian invasion
1 March 2022 - by Reuters - The U.N. agency for HIV/AIDS has said there is less than a month's worth of drugs for HIV patients left in Ukraine.
Read more...
10TH SYMPOSIUM ON HIV, LAW, AND HUMAN RIGHTS
A VIRTUAL EVENT - BILINGUAL & FREE FOR ALL
HIV Criminalization: Challenging Injustice in Canada and Around the World.
Tuesday, March 22, 1:30 - 4:00 pm (EDT).
The HIV Legal Network is hosting its 10th Symposium on HIV, Law, and Human Rights! Join us March 22nd, 2022, for HIV Criminalization: Challenging Injustice in Canada and Around the World. This virtual event will bring together people living with HIV, policymakers, legal and health professionals, along with activists and allies for a discussion about HIV and human rights.
Opinion: No comparing plights of anti-vaxxers and HIV patients
Mar 01, 2022 - Janet Butler-McPhee, Sandra Ka Hon Chu - What would it be like to live in a world with zero discrimination? How would it feel to walk through life with no fear of hate or prejudice based on your health condition? For many, this may not sound remarkable, but for many people living with HIV, it is but a dream.
Read more...
On Zero Discrimination Day, Ireland and UNAIDS strengthen their partnership to end the AIDS pandemic
DUBLIN/GENEVA, 1 March 2022 - Ireland has today announced that it is increasing its core funding for UNAIDS from €2.4 million in 2021 to €2.5 million in 2022. The announcement was made at a meeting in Dublin between Ireland’s Minister for Overseas Development Aid and Diaspora, Colm Brophy, and the Executive Director of UNAIDS, Winnie Byanyima.
Individuals considered physically attractive may boast stronger immune systems
1 March 2022 - by Beth JoJack - Scientists who study the evolution of humans have long postulated that the individuals considered the most “good-looking” may also be healthier.
Read more...
|
